Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/14/25
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/14/25
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'Seeking Alpha • 04/16/25
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol StudyZacks Investment Research • 04/15/25
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single DoseBenzinga • 04/14/25
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9GlobeNewsWire • 04/14/25
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9GlobeNewsWire • 04/11/25
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single DoseGlobeNewsWire • 03/24/25
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/27/25
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/27/25
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewsWire • 01/29/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the InvestigationAccesswire • 01/26/25
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?Zacks Investment Research • 01/23/25
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationAccesswire • 01/22/25
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities InvestigationAccesswire • 01/19/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to ConnectAccesswire • 01/15/25
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities InvestigationAccesswire • 01/12/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the InvestigationAccesswire • 01/08/25
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationAccesswire • 01/05/25